Merck & Co., Inc. is reinforcing its strength in renal cell carcinoma with data showing an overall survival benefit from the study that earned Keytruda approval in 2021 for adjuvant treatment of clear cell renal cell carcinoma in patients at intermediate-high or high risk of recurrence, but Bristol Myers Squibb Company reported data that same day for its subcutaneous formulation of Opdivo showing non-inferiority to the intravenously infused version now in use.
Key Takeaways
-
Keytruda demonstrates overall survival benefit in post-surgical RCC patients at risk of recurrence.
Both companies released the datasets 27 January at the American Society of Clinical Oncology’s 2024 Genitourinary Cancers Symposium. But while...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
